接受新辅助化疗的乳腺癌患者的光学乳腺摄影:个体化临床反应指数
本研究对10例乳腺癌患者在新辅助化疗前及每次给药时进行连续波光谱分辨光学乳腺摄影(平均12次,范围7–18次),2例因技术原因剔除。以肿瘤大小缩小>50%为反应者,化疗中点时反应者SO2下降27%±4%、[HbT]下降35±4 µM,基于SO2的累积反应指数识别反应者的敏感度和特异度均为100%。
要点
- 化疗中点时,反应者肿瘤部位SO2较基线下降27%±4%、[HbT]下降35±4 µM。
- 化疗中点时,非反应者SO2和[HbT]变化不显著。
- 基于SO2的累积反应指数在化疗中点识别反应者的敏感度和特异度均为100%。
核心结论
- 光学乳腺摄影似乎是有前景的工具,可在化疗中点评估个体对新辅助化疗的反应,以指导进一步的新辅助治疗决策。
研究设计与样本
- 光学乳腺摄影研究,采用连续波光谱分辨光学乳腺摄影,透射和平行板几何,共10例患者,2例因技术原因剔除,平均光学乳腺摄影次数12次(范围7–18次),在治疗开始前和每次新辅助化疗给药时进行;根据影像和组织病理学结果将患者分为反应者(肿瘤大小缩小>50%)和非反应者(肿瘤大小缩小<50%)。
关键影像表现/征象
- 化疗中点时,反应者(6/8)肿瘤部位SO2较基线下降27%±4%,[HbT]较基线下降35±4 µM。
- 化疗中点时,非反应者(2/8)肿瘤部位SO2和[HbT]变化不显著。
诊断标准与关键数值
- 反应者定义为肿瘤大小缩小>50%,非反应者定义为肿瘤大小缩小<50%,基于影像和组织病理学结果。
- 化疗中点时,基于SO2的累积反应指数识别反应者的敏感度为100%,特异度为100%。
临床应用与阅片要点
- 作者认为光学乳腺摄影是评估新辅助化疗个体反应的有前景工具,可在化疗中点指导进一步的新辅助治疗决策。
局限性
- 2例患者的数据因技术原因被剔除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxyhemoglobin ([HbO2]), deoxyhemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time points during chemotherapy.
MATERIALS AND METHODS: Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on 10 patients before treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12, range: 7-18). Data on two patients were discarded for technical reasons. The patients were categorized as responders (R, >50% decrease in tumor size), or nonresponders (NR, <50% decrease in tumor size) based on imaging and histopathology results.
RESULTS: At 50% completion of the NAC regimen (therapy midpoint), R (6/8) demonstrated significant decreases in SO2 (-27% ± 4%) and [HbT] (-35 ± 4 µM) at the tumor location with respect to baseline values. By contrast, NR (2/8) showed nonsignificant changes in SO2 and [HbT] at therapy midpoint. We introduce a cumulative response index as a quantitative measure of the individual patient's response to therapy. At therapy midpoint, the SO2-based cumulative response index had a sensitivity of 100% and a specificity of 100% for the identification of R.
CONCLUSIONS: These results show that optical mammography is a promising tool to assess individual response to NAC at therapy midpoint to guide further decision making for neoadjuvant therapy.
引用
- Anderson PG, Kalli S, Sassaroli A, et al. Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index. Acad Radiol. 2017. PMID: 28532642. doi:10.1016/j.acra.2017.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。